Navigation Links
CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
Date:4/8/2008

certainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
2. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
5. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
6. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
7. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:9/30/2014)... 2014 Applying a well-known optical phenomenon called ... University has demonstrated the ability to "paint" ultra-thin ... holds promise for making future, flexible electronic devices, ... of next-gen rocket ships and spacecraft with extremely ... oil in water, it becomes iridescent, revealing a ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ... has received a Canadian Patent for Inhibition or ... patent includes claims using thymosin beta 4, various ... for these purposes.  The patent will expire in ... ( www.regenerx.com ) RegeneRx is ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Ind. - Researchers are edging toward the creation ... of ultra-efficient transmission of light, with potential applications ... The metamaterial - layers of silver and titanium ... dramatically changes the properties of light. The light ...
... CRANBURY, N.J., May 25, 2012  Oncobiologics, Inc. announced ... positions with established biopharmaceutical industry experts. Stephen J. ... and Vincent J. Benn, Ph.D. has joined the ... The company also announced its new Scientific Advisory ...
... ANAHEIM, Calif., May 24, 2012 Questcor Pharmaceuticals, Inc. (NASDAQ: ... present at the Jefferies 2012 Global Healthcare Conference in New ... 8:00 a.m. ET. A live webcast and subsequent ... http://ir.questcor.com/events.cfm .  The replay will be available for approximately 90 ...
Cached Biology Technology:'Metamaterials,' quantum dots show promise for new technologies 2Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board 2Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board 3Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference 2
(Date:9/30/2014)... the environmental effects of moorland burning is published today ... with the aim of relieving tensions on both sides ... EMBER (Effects of Moorland Burning on the Ecohydrology of ... moorland, which is practised predominantly to support red grouse ... peat hydrology, peat chemistry and physical properties, river water ...
(Date:9/30/2014)... The most comprehensive assessment conducted by the Ocean ... out of 100 in overall health. In addition, ... Antarctic and the 15 ocean regions beyond national ... maintaining a healthy climate, safeguarding biodiversity and providing ... update of the index, a partnership led by ...
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... (ODS) at the National Institutes of Health (NIH) announces ... Bibliography of Significant Advances in Dietary Supplement Research. The ... by government, industry, and academic institutions, as well as ... of laboratory, human studies, and observational studies in the ...
... powerful antioxidant in green tea may prevent or delay ... Georgia researchers say. Researchers were testing EGCG, green ... 1 diabetes and primary Sjogren,s syndrome, which damages moisture-producing ... study focused on Sjogren,s syndrome, so learning that EGCG ...
... Washington, DCGeorgetown University Medical Center and Oak ... between the institutions that formalizes their research ... researchparticularly in the areas of structural biology, ... biology. The Comprehensive Research and Development ...
Cached Biology News:Annual Bibliography of Significant Advances in Dietary Supplement Research 2007 2Green tea may delay onset of type 1 diabetes 2Green tea may delay onset of type 1 diabetes 3GUMC and Oak Ridge National Labs announce unique research partnership 2GUMC and Oak Ridge National Labs announce unique research partnership 3
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Anti-Natural Killer Cell Receptor-P1, clone ... Hybridoma produced by ... BALB/c mice immunized (BALB/c X ... cells and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Biology Products: